At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 711 enrolled
Drug / intervention
TAS-118 plus Oxaliplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
In Brief
A Phase 3 clinical trial evaluating TAS-118 plus Oxaliplatin and S-1 plus Cisplatin for Gastric Cancer. Completed, enrolled 711 participants across 6 sites in 2 countries.
Detailed Summary
The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesJapan, South Korea
CollaboratorsYakult Honsha Co., LTD
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionFeb 2019
Study CompletionMay 2020
TodayJul 2026
First PostedDec 23, 2014
Enrollment StartDec 1, 2014
Primary CompletionFeb 1, 2019
Study CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.5 years ago
Interventions
TAS-118 plus Oxaliplatindrug
S-1 plus Cisplatindrug